Abstract. Studies have indicated that the immune system plays a pivotal role in hepatitis. Substance P (SP) has been shown to modulate the immune response. In order to investigate the role of SP in liver injury and to determine whether it leads to pro-inflammatory signaling, we established a mouse model of hepatic injury induced by concanavalin A (ConA). We also exposed mouse Kupffer cells (KCs) to SP in vitro. Cytokine and SP levels in liver homogenates were detected using enzyme-linked immunosorbent assay (ELISA) and the protective effects of L-703,606 were evaluated through serological and histological assessments. Neurokinin-1 receptor (NK-1R) expression was evaluated by immunofluorescence and quantitative polymerase chain reaction (PCR). The levels of SP, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly increased in the ConA-treated mice and the levels of ALT and AST were markedly reduced by L-703,606-pretreatment. Liver injury was significantly reduced by treatment with L-703,606. The mouse KCs expressed NK-1R and SP increased NK-1R mRNA expression. Furthermore, NK-1R blockade eliminated the effect of SP on NK-1R mRNA expression. The cytokine levels exhibited a substantial increase in the SP-pretreated KCs compared with the KCs that were cultured in control medium. The interleukin (IL)-6 and tumor necrosis factor (TNF)-α levels in the L-703,606-pretreated KCs were significantly lower compared with those in the SP-pretreated KCs. Our study suggests that neurogenic inflammation induced by SP plays an important role in hepatitis. Mouse KCs express NK-1R and SP increases NK-1R mRNA expression. SP enhances IL-6 and TNF-α secretion and an NK-1R antagonist inhibits this secretion.

Introduction

Inflammatory disease of the liver, i.e., hepatitis, represents a major problem in clinical medicine. Although hepatitis comprises a heterogeneous group of diseases with different etiologies and complex pathogeneses, previous studies have indicated that the immune system plays a pivotal role in the majority of these processes (1).

Neurogenic inflammation encompasses a series of inflammatory responses triggered by the activation of primary sensory neurons and the subsequent release of inflammatory neuropeptides (2). The nervous and immune systems have been shown to interact to modulate the immune response via the secretion of neuropeptides. The neuropeptide substance P (SP) is an 11 amino acid peptide encoded by the preprotachykinin-A (PPT-A) gene, which is distributed throughout the nervous systems of humans and animals (3). SP is a member of the tachykinin family of neuropeptides, which interact with three natural tachykinin (neurokinin) receptors: NK-1R, NK-2R and NK-3R (4); however, its effects are mainly mediated through NK-1R, a G protein-coupled receptor (GPCR) that is expressed in a number of tissues, including the nervous system, gastrointestinal tract and cells of the immune system. A previous study demonstrated that SP is a potent pro-inflammatory mediator that plays an important role in inflammation and viral infections (5).

SP has been shown to exert a vast range of pro-inflammatory effects in vitro and in vivo, affecting a number of immune and inflammatory disorders of the respiratory, gastrointestinal and musculoskeletal systems. Although SP is a peptide of neuronal origin, it is also located in non-neural cells, including endothelial cells, macrophages, granulocytes, lymphocytes and dendritic cells. SP stimulates immune cells to produce inflammatory cytokines, including interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), interferon (IFN)-γ and the macrophage inflam-
Substance P (SP) stimulates cytokine synthesis in Kupffer cells.

Materials and methods

Drugs and materials. ConA, L-703,606, SP, collagenase IV and Triton X-100 were purchased from Sigma (St. Louis, MO, USA). Percoll, RPMI-1640 medium and fetal bovine serum (FBS) were purchased from Gibco (Carlsbad, CA, USA). The NK-1R antibody NB300-101 and rabbit anti-NK-1R secondary antibody were purchased from Novus Biologicals (Littleton, CO, USA). IL-6 and TNF-α enzyme-linked immunosorbent assay (ELISA) kits were purchased from R&D Systems (Minneapolis, MN, USA). The other commercial chemicals used in the experiments were of analytical grade.

Animal experiments and drug treatment. Male Swiss albino mice (25-30 g) were purchased from the Experimental Animal Center of Shandong University School of Medicine, Shandong, China. The animals were housed six per cage under standard-ized conditions (25±3˚C, 12 h light/dark cycle and 50±10% humidity) with free access to pelleted food and tap water. All experiments were conducted with approval from the Institutional Experimental Animal Care and Use Committee of Shandong University.

After acclimation for 6-7 days, the animals were randomly divided into three groups, each containing 12 mice, as follows: the control group, the ConA model group and the NK-1R antagonist group (L-703,606-pretreated group). Liver injury was induced as previously described (9). ConA was dissolved in pyrogen-free phosphate-buffered saline (PBS) and intravenously injected (25 mg/kg) into the mice of the ConA model group via the tail vein. The mice in the control group were injected with saline. The mice in the NK-1R antagonist group were treated with the NK-1R antagonist L-703,606 at dose of 10 mg/kg prior to the ConA challenge. L-703,606 was dissolved in 0.9% saline and injected via the tail vein through a 27 gauge needle. Within each experiment, all drugs and doses were administered in a counterbalanced manner. Six hours later, all mice were anesthetized to enable blood to be obtained from the eye sockets and were then sacrificed prior to dissection of the liver.

Measurement of SP levels. The liver samples were thawed, weighed and homogenized at a ratio of 1:9 (w/v) in a 0.9% saline solution. The homogenate was then centrifuged at 1,600 × g for 10 min at 4˚C. The levels of SP in the supernatant were measured using a mouse SP ELISA kit according to the manufacturer's instructions. A 96-well microplate was loaded with 25 μl primary antibody specific for rat SP. Aliquots of 50 μl each sample and 50 μl standard SP dilutions (as a control) were mixed in the assigned wells in duplicate, followed by the addition of biotinylated SP to each well, with the exception of the blank control. The plate was incubated for 2 h at room temperature and then washed six times with the wash buffer provided in the kit. Subsequently, 100 μl biotinylated anti-SP antibody solution was added and the plate was incubated for 1 h and then washed four times. Then, 100 μl streptavidin-horseradish peroxidase conjugate solution was added to each well, with the exception of the chromogen blank, and the plates were incubated for 1 h and washed again. After washing, 100 μl substrate solution provided in the kit was added to each well and the plates were incubated for 1 h at room temperature. The reaction was stopped with 2 mol/l HCl and the optical density values were read at 492 nm. The concentration of SP was expressed in pg/ml.

Measuring serum liver enzymes. Blood was collected in ethylenediaminetetraacetic acid (EDTA) tubes. Following centrifugation of whole blood (1,600 x g for 10 min at room temperature), the serum was stored at -70˚C until analysis. The activities of alanine aminotransferase (ALT, a specific marker for hepatic parenchymal injury) and aspartate aminotransferase (AST, a nonspecific marker for hepatic injury) in the serum were determined in units per liter using standard auto-analyzer methods on an Hitachi Automatic Analyzer (Hitachi Inc., Tokyo, Japan).

Histological examination. The livers were removed, fixed with 4% phosphate-buffered paraformaldehyde and embedded in paraffin. Tissue sections (4 μm) were prepared and stained with hematoxylin/eosin and the sections were then examined under a light microscope. In each section, three randomly selected areas were screened for edema, granulocytes and hepatocyte apoptosis and necrosis. Histological examination was performed without knowledge of the treatment administered. The sections were examined by two independent investigators in a blind manner.

Isolation and culture of KCs. KCs from mice were isolated by collagenase digestion and differential centrifugation using Percoll density gradients as described previously (10). Livers were perfused in vitro through the vena cava with 80 ml Ca²⁺/Mg²⁺-free Hank's balanced salt solution (HBSS) at 37˚C and transferred to a 100-mm culture dish. Perfusion was continued with complete HBSS containing 0.05% collagenase IV and 3 mmol/l Ca²⁺ at 37˚C. The liver tissue was finely diced into 2-mm³-sized pieces and the suspension was incubated under constant agitation at 37˚C for 30 min. The liver homogenate was filtered through a gauze mesh and the cell
consisting of 15 min Taq activation at 95˚C followed by reverse transcription (RT)-PCR was conducted with cycling conditions 5'-GTTGCTGTAGCCAAATTCGTTGT-3'). Reverse transcription (sense: 5'-GGTGGTCTCCTCTGACTTCAACA-3'; antisense: 5'-CATCATTTTGACCACCTTGC-3'). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified as a control (sense: 5'-GCATACACCGTAGTGGGAATC-3'; antisense: 5'-GGTGGTCTCCTCTGACTTCAACA-3'; antisense: 5'-GGTGGTCTCCTCTGACTTCAACA-3').

Total NK-1R mRNA and reverse-transcribed using the AffinityScript qPCR cDNA synthesis kit (Stratagene, Cedar Creek, TX, USA) and analyzed using Image Pro Plus 6.0 (Media Cybernetics Rockville, MD, USA). Images were acquired by laser scanning confocal microscopy (LSM710; Carl Zeiss, Oberkochen, Germany) and analyzed using Image Pro Plus 6.0 (Media Cybernetics Rockville, MD, USA).

**NK-1R immunofluorescence.** Cells (5x10⁴) were plated on poly-L-lysine-coated slides in 200 µl media, fixed with 4% paraformaldehyde, washed three times in 0.1 M PBS, blocked with serum-free protein and permeabilized using 0.4% Triton X-100. The fixed cells were incubated overnight at 4˚C with the NK-1R antibody NB300-101 (1:50), then subjected to PBS washes and incubation with rabbit anti-NK-1R secondary antibody (1:500) for 1 h at room temperature. Then, the sections were washed in PBS and mounted with 4',6-diamidino-2-phenylindole (DAPI)-containing mounting medium (Vector Laboratories, Burlingame, CA, USA). Images were acquired by laser scanning confocal microscopy (LSM710; Carl Zeiss, Oberkochen, Germany) and analyzed using Image Pro Plus 6.0 (Media Cybernetics Rockville, MD, USA).

**Measurement of cytokine release.** Micromolar concentrations of SP are typically used during in vitro studies to identify the biological effects on immune cells, particularly monocytes (12). KCs were seeded into 24-well plates at a density of 1x10⁵ cells/well and incubated with fresh Dulbecco's modified Eagle's medium (DMEM) containing 1 µg/ml LPS at 37˚C with 5% CO₂. The KCs were cultured with and without SP or with a combination of SP and L-703,606 with fresh Dulbecco's modified Eagle's medium (DMEM) containing 1 µg/ml LPS at 37˚C with 5% CO₂ and challenged with SP (10⁶ M) for 24 h. A dose of 1 µM (10⁻⁶ M) SP and a stimulation time of 24 h were selected to ensure maximal cytokine release, as observed in a previous study (13). At this concentration, SP is reported to stimulate significant chemokine production by pancreatic acinar cells and prime neutrophils triggered by different stimuli to evoke various cellular responses, including intracellular calcium changes, oxidative responses and the formation of hydrogen peroxide and nitric oxide (14,15). In some experiments, the cells were pretreated with L-703,606 (1 µM) for 15 min before SP stimulation, as previously described (16). The medium from the cultured KCs was collected and centrifuged at 1,000 x g for 5 min and the supernatant was stored at -70˚C until the assays. The IL-6 and TNF-α levels in the supernatant were determined using mouse-specific ELISA kits. All samples, including the standard and control solutions, were assayed in duplicate. The measurements were performed according to the manufacturer's instructions. No cross-reactivity was observed with any other known cytokine. The results are expressed in picograms per milliliter.

**Statistical analysis.** All data are presented as mean ± standard error of the mean (SEM). Differences among the groups were assessed using unpaired Student's t-tests and one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference. The calculations were performed with the SPSS, version 11.0, statistical software package (SPSS, Inc., Chicago, IL, USA).

**Results**

Detection of SP and liver function. As shown in Table I, the levels of SP were significantly increased in the ConA model group. SP, substance P; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ConA, concanavalin A.

| Groups                      | ALT (U/l)    | AST (U/l)    | SP (pg/ml) |
|-----------------------------|--------------|--------------|------------|
| Control group               | 42.05±8.31   | 51.12±9.16   | 138.52±13.23 |
| ConA model group            | 782.37±21.51 | 1004.25±18.24 | 387.23±29.36 |
| L-703,606-pretreated group  | 402.22±16.42 | 581.45±17.51 |            |

Results are presented as mean ± standard error of the mean (SEM; n=12 mice per group). *P<0.05 vs. the control group; †P<0.05 vs. the ConA model group. SP, substance P; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ConA, concanavalin A.
Marker determinations revealed that serum ALT and AST levels were significantly increased in the ConA-treated group compared with those in the control group. However, the levels of serum ALT and AST were significantly decreased in the L-703,606-pretreated group compared with those in the ConA-treated group.

**Histopathological changes.** A model of hepatic immune injury in mice was successfully established in this study. Our histological observations revealed that edema, hepatocellular apoptosis and granulocyte infiltration were present in the livers of the ConA model group. Compared with those of the control group (Fig. 1A), the liver tissues from the mice in the ConA-treated group exhibited significant cytoplasmic vacuolization, sinusoidal congestion, extensive hepatic cellular necrosis and massive cellular infiltration (Fig. 1B). However, the parenchymal appearance was essentially normal in the L-703,606-pretreated group. Mild cellular infiltration, necrosis and a comparatively preserved lobular architecture were observed in the livers of mice treated with L-703,606 (Fig. 1C). The NK-1R antagonist L-703,606 was shown to significantly alleviate ConA-induced liver injury. These results suggest a therapeutic significance of L-703,606 for protection from ConA-induced liver injury.

**Mouse KCs express NK-1R and SP increases NK-1R mRNA expression in KCs in vitro.** NK-1R was analyzed in KCs from mice, based on immunohistochemical localization using fluorescein. The immunoreactivity was concentrated in the cell cytoplasm (Fig. 2A), which is different from the results of other studies (8). NK-1R mRNA levels were upregulated in KCs incubated with SP for 24 h. According to quantitative PCR, the results further demonstrated that SP increased NK-1R mRNA expression 2.5-fold (Fig. 2B). NK-1R blockade eradicated the effect of SP on NK-1R mRNA expression and significantly reduced NK-1R mRNA expression to below the level observed in control culture medium.
Table II. IL-6 and TNF-α levels in the different groups.

| Group                      | IL-6 (pg/ml) | TNF-α (pg/ml) |
|----------------------------|--------------|---------------|
| Control group              | 71.13±9.36   | 31.02±7.26    |
| SP-pretreated group        | 194.12±11.09a | 92.15±8.56a   |
| L-703,606-pretreated group | 68.16±9.51a  | 28.38±5.04a   |

Values are presented as mean ± standard error (SE). "P<0.05 compared with the control group; "P<0.05 compared with the SP group. SP; substance P; IL, interleukin; TNF, tumor necrosis factor.

SP enhances IL-6 and TNF-α secretion and L-703,606 inhibits SP-induced IL-6 and TNF-α release from KCs in vitro. In order to determine whether SP-induced IL-6 and TNF-α release is mediated through the NK-1R, KCs were pre-incubated with the NK-1R antagonist L-703,606 (10 µM) for 15 min and during stimulation with SP (1 µM). As shown in Table II, the cytokine (IL-6 and TNF-α) levels in the supernatant resulting from the release from cultured KCs revealed a substantial increase in the SP-pretreated group compared with the control group. The IL-6/TNF-α levels of the supernatant in the L-703,606-pretreated group were significantly lower compared with those in the SP-pretreated group. In other words, the SP-induced IL-6 and TNF-α secretion from KCs was eradicated by pretreatment with L-703,606.

Discussion

Various factors, including viral infections, autoimmune reactions and metabolic disorders are involved in liver injury. ConA-induced hepatitis, which closely mimics the pathogenesis mechanisms and pathological changes of patients, has long been regarded as an appropriate model of human immune-mediated liver disease (17). ConA is a type of lectin, which is purified from Canavalia brasiliensis. The mechanisms of the ConA model have interested numerous scientists; when mice are treated with ConA, lymphocytes and other mononuclear cells release lymphokines and there is a rapid inflammatory alteration of the liver tissue, including clear infiltration of neutrophils, macrophages and T cells, as well as a significant simultaneous increase in the level of arachidonic acid metabolites and pro-inflammatory cytokines; the release of an array of inflammatory mediators, growth factors and reactive oxygen species, including TNF-α and IL-6, which contribute to hepatocellular damage (26). Furthermore, accumulating evidence indicates that activation of KCs prevents liver injury (27). Therefore, the factors that control the KC response are clearly critical in the progression of liver injury. SP has been shown to affect cytokine production and release from various immune cells. For example, SP modulates the release of IL-1, IL-6 and TNF-α from human blood monocytes (12). In monocytes and macrophages, SP also stimulates the release of arachidonic acid metabolites and pro-inflammatory cytokines; it induces the respiratory burst and acts as a potent chemoattractant (28). SP has been detected in the liver, and receptors for SP have also been detected on KCs and hepatocytes. However, there is limited information concerning the correlation between SP and cytokines in KCs. Previous studies have indicated that NK-1Rs are upregulated at sites of inflammation in a number of tissues, including joints and the intestine (29-31). The current study demonstrates that mouse KCs expressed NK-1R and that treatment with SP increased NK-1R mRNA expression in KCs in vitro. However, at this early stage, the cytokine (IL-6 and TNF-α) levels in the supernatant resulting from the release from cultured KCs without LPS were below the minimum detection range (data not shown). Although LPS was involved in the experiment, it did not affect our study since the three groups of KCs were all incubated with it. The cytokine (IL-6 and TNF-α) levels are shown in Table II. To the best of our knowledge, we report for the first time that SP induces IL-6 and TNF-α production in KCs. In the current study, L-703,606 exhibited strong activity by reducing the production of TNF-α and IL-6 in SP+LPS-stimulated KCs, suggesting that the inhibition of pro-inflammatory cytokine (TNF-α and IL-6) release by KCs may contribute to L-703,606-mediated liver protection. Further in vivo and in vitro studies are required to determine the exact molecular pathways affected by L-703,606, which may be useful in the development of novel treatments for hepatic injury and fibrosis.

In summary, the present study and our previous findings indicate that inflammatory cytokine-mediated apoptotic liver injury is affected by neuropeptides. NK-1R agonists, including SP appear to be major players in this scenario by upregulating the pro-inflammatory cytokine response. If
the data from our mouse experiments on the hepatoprotective potential of NK-1R antagonists is transferred to clinical practice, it is likely to have potential clinical implications, providing a future strategy for therapeutic intervention in the treatment of liver injuries through the suppression of KC activation and pro-inflammatory cytokines. Moreover, these findings may offer novel therapeutic targets for ameliorating liver fibrosis and cirrhosis progression. In future experiments we aim to investigate whether SP is as important in chronic liver injury as it is in acute liver injury; this may provide new avenues of investigation for the treatment of acute and chronic liver inflammation. Specifically, further studies focusing on whether SP plays a role in other biological processes of KCs, including proliferation, survival and migration, are required to improve our understanding.

Acknowledgements

This study was funded by Qilu Hospital of Shandong University.

References

1. Mackay IR: Immunological aspects of chronic active hepatitis. Hepatology 3: 724-728, 1983.
2. Richardson JD and Vasko MR: Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 302: 839-845, 2002.
3. Sternberg EM: Neural regulation of innate immunity: a coordinated nonspecific host response to pathogens. Nat Rev Immunol 6: 318-328, 2006.
4. Greco SJ, Corcoran KE, Cho KJ and Rameshwar P: Tachykinins in the emerging immune system: relevance to bone marrow homeostasis and maintenance of hematopoietic stem cells. Front Biosci 9: 1782-1793, 2004.
5. Satake H and Kawada T: Overview of the primary structure, tissue-distribution, and functions of tachykinins and their receptors. Curr Drug Targets 7: 963-974, 2006.
6. Sterner-Kock A, Braun RK, van der Vliet A, et al: Substance P primes the formation of hydrogen peroxide and nitric oxide in human neutrophils. J Leukoc Biol 65: 834-840, 1999.
7. Bang R, Biberger M, Neuhuber WL and Tiefs G: Neurokinin-1 receptor antagonist A-83552 protects mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage. J Pharmacol Exp Ther 308: 1174-1180, 2004.
8. Bang R, Sass G, Kierner AK, Vollmar AM, Neuhuber WL and Tiefs G: Neurokinin-1 receptor antagonists CP-96,345 and A-83552 protect mice from endotoxin-induced liver injury. J Pharmacol Exp Ther 305: 31-39, 2003.
9. Kunste G, Hentze H, Germann PG, et al: Concanavalin A hepatotoxicity in mice: tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation. Hepatology 30: 1241-1251, 1999.
10. Smesti B and Pertoff H: Preparation of pure hepatocytes and reticuloendothelial cells in high yield from a single rat liver by means of Percoll centrifugation and selective adherence. J Leukoc Biol 38: 213-230, 1985.
11. Lai WP, Douglas SD, Wang YJ and Ho WZ: Real-time reverse transcription-PCR quantitation of substance P receptor (NK-1R) mRNA. Clin Diagn Lab Immunol 12: 537-541, 2005.
12. Lotz, M, Vaughan JH and Carson DA: Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241: 1218-1221, 1988.
13. Amoroso A, Bardelli C, Gunella G, Ribichini F and Brunelleschi S: A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages. Br J Pharmacol 154: 144-152, 2008.
14. Dianzani C, Lombardi G, Collino M, Ferrara C, Cassone MC and Fantozzi R: Priming effects of substance P on calcium changes evoked by interleukin-8 in human neutrophils. J Leukoc Biol 69: 1013-1018, 2001.
15. Ramnath RD and Bhatia M: Substance P treatment stimulates chemokine synthesis in pancreatic acinar cells via the activation of NF-kappaB. Am J Physiol Gastrointest Liver Physiol 291: G1113-G1119, 2006.
16. Barreto SG, Carati CJ, Schlothe AC, et al: The combination of neurokinin-1 and galanin receptor antagonists ameliorates caerulein-induced acute pancreatitis in mice. Peptides 31: 315-321, 2010.
17. Kaneko Y, Harada M, Kawano T, et al: Augmentation of NF-kappaB cDNA cell-mediated cytotoxicity by interleukin-4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J Exp Med 191: 105-114, 2000.
18. Miyazawa Y, Tsutsui H, Mizuhrara H, Fujiiwa H and Kaneda K: Involvement of intrasinusoidal homestasis in the development of concanavalin A-induced hepatic injury in mice. Hepatology 27: 497-506, 1998.
19. Neuhuber WL and Tiefs G: Innervation of immune cells: evidence for neuroimmunomodulation in the liver. Anat Rec A Discov Mol Cell Biol Evol Biol 280: 884-892, 2004.
20. Bhatia M, Zhi L, Zhang H, Ng SW and Moore PK: Role of substance P in hydrogen sulfide-induced pulmonary inflammation in mice. Am J Physiol Lung Cell Mol Physiol 289: L986-L994, 2006.
21. Chauhan VS, Kluttz JM, Bost KL, et al: Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis. J Immunology 180: 7255-7263, 2011.
22. Vollmar B and Menger MD: The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 89: 1269-1339, 2009.
23. Carini R and Albano E: Recent insights on the mechanisms of liver preconditioning. Gastroenterology 125: 1480-1491, 2003.
24. Hildebrand F, Hubbard WJ, Choudhry MA, et al: Kupffer cells and their mediators: the culprits in producing distant organ damage after trauma-hemorrhage. Am J Pathol 169: 784-794, 2006.
25. Solga SF and Diehl AM: Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 38: 681-687, 2003.
26. Koo DJ, Chaudry IH and Wang P: Kupffer cells are responsible for producing inflammatory cytokines and hepatocellular dysfunction during early sepsis. J Surg Res 83: 151-157, 1999.
27. Wang YY, Dahle MK, Agren J, et al: Activation of the liver X receptor protects against hepatic injury in endotoxia by suppressing Kupffer cell activation. Shock 25: 141-146, 2006.
28. O'Connor TM, O'Connell J, O'Brien DJ, Goode T, Bredin CP and Shanahan F: The role of substance P in inflammatory disease. J Cell Physiol 201: 167-180, 2004.
29. Reed KL, Fruin AB, Gower AC, et al: NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 50: 2366-2378, 2005.
30. Keeble J, Blades M, Pitzalis C, Castro da Rocha FA and Brain SD: The role of substance P in microvascular responses in murine joint inflammation. Br J Pharmacol 144: 1059-1066, 2005.
31. Karagiannides I, Kokotou E, Tansky M, et al: Induction of colitis causes inflammatory responses in fat depots: evidence for substance P pathways in human mesenteric paeidocytes. Proc Natl Acad Sci USA 103: 5207-5212, 2006.